Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients
Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.
Bristol Myers tested a new cancer medicine on very sick patients, and it worked better than expected. When a company's medicine does well in testing, it shows their work is on track and people watch to see if it might help more patients someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.